Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
Pérez MS, Rodríguez-Capitán J, Requena-Ibáñez JA, Santos-Gallego CG, Urooj Zafar M, Escolar G, Mancini D, Mitter S, Lam D, Contreras JP, Fergus I, Atallah-Lajam F, Abascal V, Lala A, Moreno P, Moss N, Lerakis S, Sanz J, Fuster V, Badimon JJ.
Pérez MS, et al.
Cardiovasc Drugs Ther. 2023 Jun 15. doi: 10.1007/s10557-023-07469-6. Online ahead of print.
Cardiovasc Drugs Ther. 2023.
PMID: 37318685